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ABSTRACT
The objectives of this study were to develop transplantation regimens for patients with advanced myelodysplastic
syndrome (MDS) that would be associated with low transplantation-related mortality and improved relapse-free
survival. Sixty patients with advanced MDS or acute myeloid leukemia evolving from MDS (sAML), 12 to 62 years
old (median, 40 years), were conditioned with busulfan (7 mg/kg) and TBI (6 × 200 cGy) (BU/TBI) and received
transplants from related (n = 20) or unrelated donors (n = 40). By French-American-British (FAB) criteria, 21 patients
had refractory anemia with excess blasts (RAEB), 16 had RAEB in transformation (RAEB-T), 15 had sAML, and
8 had chronic myelomonocytic leukemia (CMML). By International Prognostic Scoring System (IPSS) criteria,
1 patient had low, 10 had intermediate-1, 13 had intermediate-2, and 31 had high-risk MDS (5 patients had prolif-
erative CMML). All evaluable patients achieved sustained engraftment. The cumulative incidence (CI) of acute
GVHD grades II to IV was 83% with unrelated donors and 85% with related donors. The CI of relapse was 25% at
3 years. The incidence of nonrelapse mortality (NRM) at 100 days was 38%. The Kaplan-Meier estimate of sur-
vival was 26% at 3 years. Major causes of death were relapse, organ failure, GVHD, and infection. In multivariate
analysis, improved relapse-free survival was associated with good cytogenetic risk (P = .002) and shorter disease
duration (P = .004). NRM was increased with longer disease duration (P = .0002), positive cytomegalovirus serol-
ogy (P = .02), and male sex (P = .02). Relapse was associated with poor cytogenetic risk (P = .0004). Thus, BU/TBI
conditioning as used in this trial was associated with relapse rates comparable to those observed with a previously
used more intensive regimen combining BU/TBI with cyclophosphamide. However, despite the omission of
cyclophosphamide, transplantation-related morbidity and mortality were considerable, particularly with trans-
plants from unrelated donors. Future trials should explore the efficacy and tolerability of reduced-intensity condi-
tioning regimens.
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INTRODUCTION
Patients with advanced myelodysplastic syndrome (MDS)
have a poor prognosis due to complications related to periph-
eral blood cytopenias and the high probability of transforma-
tion into secondary acute myeloid leukemia (sAML). Using
the criteria of the French-American-British (FAB) classiﬁca-
tion, median survival times for patients with refractory ane-
mia with excess blasts (RAEB), refractory anemia with excess
blasts in transformation (RAEB-T), and chronic myelomono-
cytic leukemia (CMML) [1] have been reported to be 9, 6,
and 22 months, respectively. The International Prognostic
Scoring System (IPSS), which considers cytogenetic abnor-
malities and the number of peripheral blood cytopenias in
addition to the proportion of marrow blasts, appears to add
prognostic accuracy in predicting survival and evolution to
AML for patients with “de novo” MDS [2-6].
Hematopoietic stem cell transplantation (HSCT) is cur-
rently the only curative therapy for MDS [7]. However, in
patients receiving transplants for advanced MDS, relapse
rates of 30% to 50% and nonrelapse mortality (NRM) rates
of 35% to 50% have resulted in event-free survivals of 15%
to 30% [8]. High-risk IPSS scores, in particular the number
of blasts (in marrow and blood), and unfavorable cytoge-
netic abnormalities are major determinants of high relapse
rates [3-6,9-15]. Older patient age, longer disease duration,
and male sex also have predictive value for higher NRM
[9,10,12-15].
Trials at the Fred Hutchinson Cancer Research Center
[10] showed that patients with advanced MDS conditioned
with cyclophosphamide (CY) and total body irradiation
(TBI) had a relapse incidence of 39% and a probability of
survival of 30% at 3 years. The addition of busulfan (BU;
7 mg/kg) to a CY/TBI regimen led to a lower relapse rate
(19%); however, with such a regimen, the incidence of NRM
was 57% and relapse-free survival (RFS) was only 23% [11].
CY does not have anti–stem cell activity but may contribute
to nonhematologic toxicity. Therefore, in an attempt to
improve RFS, the present trial used a combination of BU
(7 mg/kg) and TBI (6 × 200 cGy) without the inclusion of
CY. To put results into perspective, outcomes in the present
trial were compared to those observed after CY/TBI or
BU/CY/TBI conditioning as reported previously [11].
MATERIALS AND METHODS
Patients
From January 1994 through October 1999, 60 patients
with advanced MDS or MDS transformed into AML
(sAML) were enrolled in this study. Patient characteristics
are summarized in Table 1. At the time of diagnosis, 13 of
these patients had RA; 28 patients had RAEB; 9 patients had
RAEB-T; and 10 patients had CMML. Forty-eight of the
60 patients had de novo MDS, and 12 patients had disease
considered secondary to previous therapy for acute lym-
phoblastic leukemia (n = 3), aplastic anemia (n = 2), Hodg-
kin’s disease (n = 1), multiple myeloma (n = 1), breast cancer
(n = 1), kidney transplantation (n = 1), systemic lupus ery-
thematosus (n = 1), bare lymphocyte syndrome (n = 1), or
pesticide exposure (n = 1). All patients with secondary MDS
were in complete remission from the original disease. Five
patients had not received therapy for MDS before trans-
plantation; all remaining patients had been treated with
transfusion support, vitamins, growth factors, or other
modalities. Two patients had undergone splenectomy. At the
time of HSCT, 21 patients had RAEB; 16 patients had
RAEB-T; 15 patients had sAML; and 8 patients had
CMML. Eighteen patients (3 with RAEB, 4 with RAEB-T,
8 with sAML, and 3 with CMML) received induction
chemotherapy on protocols that included cytosine arabi-
noside and an anthracycline or topotecan, and 8 of these
patients (2 with RAEB, 1 with RAEB-T, 4 with sAML, and
1 with CMML) achieved complete hematologic remissions
(CR) and were in CR at the time of HSCT. Ten patients had
no or only partial responses. The interval from diagnosis of
MDS to HSCT for all patients was 2 to 61 months (median,
12 months; 6.6 months for related and 14.7 months for
unrelated transplantation).
Table 1. Patient and Disease Characteristics*
Conditioning Regimen
BU/TBI BU/CY/TBI CY/TBI
Characteristic (Present Study) [11] [11]
No. of patients 60 31 44
Age, range (median), y 12-62 (40) 16-54 (41) 1-55 (36)
M/F, no. of patients 37/23 18/13 25/19
Etiology, no. of patients
De novo 48 28 37
Secondary 12 3 7
Disease duration, range 2-61 (12) 2-83 (5) 2-144 (8.5)
(median), mo
FAB stage, no. of patients
RAEB 21 15 30
RAEB-T 16 8 14
CMML 8 8 0
sAML 15 0 0
Cytogenetic risk (IPSS), 
no. of patients
Good 24 15 14
Intermediate 11 6 9
Poor 25 10 19
Not available 0 0 2
IPSS group, no. of patients
Low 1 0 ND†
Intermediate–1 10 9 ND
Intermediate–2 13 9 ND
High 31 6 ND
Not scored‡ 5 7 ND
CMV serology, no. of patients
Positive 31 26 28
Negative 29 5 16
GVHD prophylaxis, no. of 
patients
MTX/CSP 53 15 44
MTX/FK506 7 2 0
CSP/MP 0 10 0
CSP 0 4 0
Donor
HLA-identical sibling 17 22 33
Alternative donor§ 43 9 11
*ND indicates not determined; MP, methylprednisolone.
†Not determined; not all parameters complete.
‡Proliferative CMML.
§HLA-nonidentical related or unrelated donor.
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Cytogenetic Characteristics.At the time of diagnosis of
MDS, cytogenetic data were available in 54 patients. By IPSS
criteria [2], 20 patients were categorized as good risk (normal
karyotype in 19 patients; 5q– in 1 patient), 19 patients as poor
risk (chromosome 7 abnormalities in 10 patients; complex
abnormalities in 9 patients), and 15 patients as intermediate
risk (trisomy 8 in 3 patients; miscellaneous abnormalities
in 12 patients). At the time of HSCT, cytogenetic analy-
sis was performed in all patients: 24 of them were good
risk (normal karyotype in 23 patients; 5q– in 1 patient),
25 patients were poor risk (chromosome 7 abnormalities in
16 patients; complex abnormalities in 9 patients), and
11 patients were intermediate risk (trisomy 8 in 3 patients,
single miscellaneous in 5 patients, and double abnormalities
in 3 patients).
IPSS Scores. Although the IPSS was developed for
patients with de novo MDS [2], in the present analysis, we
applied the IPSS criteria to all patients except those with
proliferative CMML. At HSCT, 1 patient qualiﬁed as low risk,
10 patients as intermediate-1, 13 patients as intermediate-2,
and 31 patients as high risk. Five patients had proliferative
CMML.
Conditioning Regimen
BU (0.44 mg/kg) was given orally every 6 hours for
16 doses on days –7 to –4 for a total of 7 mg/kg. Because
plasma BU concentrations at steady state (BU Css) can vary
widely among patients [16], sequential plasma samples for
pharmacokinetic monitoring were obtained. BU Css levels
ranged from 247 to 627 ng/mL (median, 450 ng/mL) [17].
TBI was delivered at an exposure rate of 6 to 7 cGy/min in
fractions of 200 cGy twice daily on days –3 to –1 for a total
dose of 1200 cGy.
Source of Hematopoietic Stem Cells
Twenty patients received HSCT from related donors
(17 were HLA genotypically identical and 3 were HLA-A,
-B, -DR phenotypically matched), and 40 patients received
transplants from unrelated donors (38 were HLA-A, -B, -C
serologically matched and DRB1 matched; 1 donor was
serologically mismatched for HLA-C, and 1 for HLA-A).
The source of hematopoietic stem cells was marrow in
58 patients and peripheral blood in 2 patients (both related
transplants); all transplants were T-cell replete. Median
mononuclear cell dose was 3.35 × 108/kg for marrow recipi-
ents and 13.6 and 5.9 × 106 CD34+ cells/kg, respectively, for
the 2 recipients of peripheral blood.
Graft-Versus-Host Disease Prophylaxis
Graft-versus-host disease (GVHD) prophylaxis consisted
of a short course of methotrexate (MTX) and cyclosporine
(CSP) in 53 patients and tacrolimus (FK 506) and MTX in
7 patients, as described previously [18,19]. Acute and chronic
GVHD were diagnosed and graded as described [20,21].
Acute GVHD was treated with prednisone, monoclonal anti-
bodies, or rapamycin [22,23] Chronic GVHD was treated
with prednisone alone or combined with CSP.
Engraftment and Rejection
The day of engraftment was defined as the first of 3
consecutive days on which neutrophil counts exceeded
0.5 × 109/L [24]. Evidence of graft rejection was sought in
patients who survived at least 28 days and who failed to
reach 0.5 × 109 neutrophils/L and in patients who showed a
decline after initial recovery. In patients with morphologic
or cytogenetic evidence of recurrence of MDS, relapse
rather than rejection was considered the cause of graft fail-
ure as long as donor T-lymphocytes persisted (see below).
When patient and donor were of different sexes, in situ
hybridization with X- and Y-chromosome probes [25] was
performed on bone marrow and peripheral blood mononu-
clear cells (PBMC) stimulated with phytohemagglutinin to
determine donor versus host origin. When patient and
donor were of the same sex, DNA from bone marrow and
PBMC was amplified for several variable number tandem
repeat (VNTR) loci. The ampliﬁed fragments were exam-
ined to identify informative host and donor markers [26].
Relapse
All patients were scheduled to have marrow samples
examined morphologically and by cytogenetic and flow
cytometric analyses at a minimum on day 28, at 3 months
after transplantation, and then annually or as clinically indi-
cated. Relapse was deﬁned as the detection of metaphases in
the marrow that showed the same clonal marker(s) identi-
fied before transplantation or as the reemergence of
myeloblasts or aberrant precursors as deﬁned with the use of
ﬂow cytometry [27].
Infection
Blood samples were examined weekly for evidence of
cytomegalovirus (CMV) either by culture or by the presence
of CMV antigenemia. Interstitial pneumonia (IP) was diag-
nosed by culture, histologic or histochemical analysis of
bronchoalveolar lavage ﬂuid, open lung biopsy, or autopsy.
Various strategies to prevent infections were employed dur-
ing this study, including the prophylactic use of systemic
antibiotics, fluconazole, acyclovir, and ganciclovir. All
CMV-seronegative patients received either CMV-negative
or ﬁltered blood products. Acyclovir was given for prophy-
laxis throughout the study period to all patients who were
seropositive for herpes simplex virus. Ganciclovir was given
to all CMV-seropositive recipients at engraftment or at the
ﬁrst documentation of antigenemia [28].
Causes of Death
Relapse was considered the primary cause of death for
all deaths after relapse. Deaths in the absence of relapse
were categorized as NRM. Infections were categorized
according to whether or not they were associated with
GVHD and with organ failure. Multiorgan failure was con-
sidered the cause of death if decompensation occurred in at
least 2 organ systems (eg, liver and kidneys or liver and
lungs) not associated with GVHD or infection.
Historical Controls
In an attempt to put results of the present trial into per-
spective, we also included data on 2 previously reported tri-
als: 31 patients who received transplants from 1990 through
1993 after conditioning with BU/CY/TBI and 44 patients
who received transplants from 1982 through 1990 after con-
ditioning with CY/TBI [11] (Table 1).
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Statistical Analysis
RFS probabilities were estimated using the Kaplan-Meier
method [29]. The incidences of relapse and NRM were
expressed as cumulative incidence (CI) [30]. Cox regression
was used to analyze risk factors related to the hazard rates for
these outcomes. In these analyses, relapse and NRM were
considered as competing events. The time to these outcomes
was censored at the time of a competing event. Multivariate
models were constructed by a forward selection procedure. At
each step, the most signiﬁcant factor at a level of at least 0.05
was added. Multivariate P values refer to the signiﬁcance of
the factor after adjusting for other factors in the ﬁnal multi-
variate model. All P values are 2-sided and are based on likeli-
hood ratio statistics from the Cox regression model. Results
were analyzed as of June 1, 2001.
In addition, we compared the present data with those
reported previously for CY/TBI and BU/CY/TBI condi-
tioned patients [11].
RESULTS
Engraftment
Eight patients died on days 11 through 27 (see Table 2)
and were considered unevaluable for engraftment. The
remaining 52 patients achieved granulocyte counts >0.5 ×
109/L at 11 to 33 days (median, 19 days) and platelet counts
>20 × 109/L at 10 to 47 days (median, 23 days); there were
no significant differences between related and unrelated
transplant recipients. All surviving patients had complete
donor engraftment as determined by chimerism analysis at
3 months and 1 year after transplantation.
Graft-Versus-Host Disease
Acute GVHD grades II to IV occurred in 50 evaluable
patients (grade II in 20 patients [10 related/10 unrelated],
grade III in 19 patients [5/14], and grade IV in 11 patients
[9/2]). The incidences of grades II to IV acute GVHD were
85% and 83% for related and unrelated donors, respectively.
Twenty (8 related/12 unrelated) among 29 (11 related/
18 unrelated) patients at risk developed extensive chronic
GVHD for a CI of 70%.
Survival
With a follow-up of 20 to 89 months (median,
54 months), 16 patients are alive, and 15 of them are in CR,
with Karnofsky performance scores of 90 to 100 in
11 patients and 50 to 80 in the remaining 5 patients. The
3-year RFS was 26% for the entire cohort, and 31% when
sAML cases were excluded. Three-year RFS was 13% for
patients with sAML. RFS was 31% for patients with de novo
MDS and 8% for patients with secondary MDS (P = .11).
There was no signiﬁcant difference in RFS between patients
receiving transplants from related donors (30%) and those
receiving transplants from unrelated donors (25%) (Fig-
ure 1A). One of the 2 patients receiving transplants from
HLA-mismatched unrelated donors is surviving.
Relapse
Sixteen patients, 13 of whom had high-risk IPSS scores,
relapsed 0.5 to 49 months (median, 3.7 months) posttrans-
plantation; all but 2 relapses occurred within 9 months. The
incidence of relapse at 3 years was 25% for the entire group
Table 2. Causes of Death Among Patients Conditioned With BU/TBI*
Cause of Death No. of Deaths (Before Day 28)
Relapse 14
Organ failure ± infection ± GVHD 19 (5)
GVHD ± infection 4
Infection 4 (2)
Infection + PTLD 1
CNS hemorrhage 2 (1)
*PTLD indicates posttransplantation lymphoproliferative disorder;
CNS, central nervous system.
Figure 1. Outcome in patients with advanced MDS who received
transplants from related or unrelated donors. All patients were condi-
tioned with BU and TBI. X indicates censored patients. A, Relapse-free
survival (P = NS). B, Incidence of relapse (P = NS). C, Non-relapse
mortality (P = NS).
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(35% for related and 20% for unrelated transplants) (Fig-
ure 1B). The relapse incidence was 47% for patients with
sAML and 18% for other patients. One patient who
relapsed at 9 months received a donor lymphocyte infusion
(2.75 × 107 CD3+ cells/kg) and achieved another CR. Four-
teen patients died with disease progression, and 1 patient is
alive with recurrent disease.
Among the 8 patients who achieved pretransplantation
CR with induction chemotherapy, 2 patients are surviving in
CR (1 following donor lymphocyte infusion; see above) and
1 patient is alive in relapse. Five patients have died, 1 from
relapse and 4 from NRM. Among the 10 patients who did
not respond to chemotherapy, 1 patient is alive in CR, and
9 patients have died, 3 from relapse and 6 from NRM.
Nonrelapse Mortality
Thirty patients died from transplantation-related com-
plications, for a NRM of 49% (35% for related and 55% for
unrelated transplants; P = NS; Figure 1C). The NRM inci-
dence was 40% for patients with sAML and 51% for other
patients (P = NS). Twenty-two patients died before day 100,
including 8 patients who died before day 28. The causes of
death are listed in Table 2. The most frequent cause was sin-
gle or multiorgan failure, alone or associated with infection,
GVHD, or both. The most frequent etiology of infection
was fungal (n = 10), specifically, aspergillus species in
9 patients and mucor in 1 patient.
Univariate Analysis
Results are summarized in Table 3. Patients with poor-
risk cytogenetics had a lower RFS (14%) and a higher
relapse rate (43%) than did good- and intermediate-risk
patients (RFS, 33%; P = .02; relapse rate, 15%; P = .0004).
Other signiﬁcant variables for lower relapse rates were the
diagnosis of RAEB (P = .02) and low/intermediate-1 IPSS
scores at transplantation (P = .003). Conversely, the diagno-
sis of sAML was predictive of a higher relapse rate (P = .02).
FAB category or IPSS score at the time of diagnosis of MDS
had no significant impact on outcome. Disease duration
>12 months was also predictive for lower RFS (17%; P =
.007) and was associated with higher NRM (79%; P = .001).
Outcomes tended to be better with lower BU Css levels, but
differences were not significant for any of the endpoints
studied. Although patients with de novo MDS tended to
fare better than patients with secondary MDS, differences
did not reach statistical signiﬁcance for any of the endpoints
studied (RFS, 31% versus 8%, P = .14; relapse, 23% versus
33%, P = .24; NRM, 46% versus 58%, P = .33). Patient age
and transplantation from unrelated compared to related
donors had no signiﬁcant impact on outcome.
Multivariate Analysis
Results are as summarized in Table 4. Cytogenetic risk
category was the only factor associated with relapse (P =
.0004), which also affected RFS (P = .004) (Figure 2). Dis-
ease duration >12 months was signiﬁcantly associated with
higher NRM (P = .0002) and reduced RFS (P = .002). In
Table 3. Probability of RFS, Relapse, and NRM Among BU/TBI 
Conditioned Patients: Univariate Analysis*
Endpoint, % at 3 y
Risk Factor RFS Relapse NRM
All patients 26 25 49
Patient sex
Female 35 39 26
Male 21 17 63
P .36 .25 .04
Disease duration
<12 months 32 29 39
>12 months 7 14 79
P .007 .95 .001
Cytogenetic pattern
Good/intermediate 33 15 51
Poor 14 43 43
P .02 .0004 .72
IPSS risk
Low/intermediate-1 46 9 46
Intermediate-2 31 8 62
High 16 39 45
Not available 40 20 40
P .04 .003 .65
FAB classification
RAEB 37 10 53
RAEB-T 25 25 50
sAML 13 47 40
CMML 25 25 50
P .22 .02 .92
*Not signiﬁcant for any of the 3 endpoints were patient age, disease
etiology, donor relationship (related versus unrelated), and steady-state
plasma BU levels.
Table 4. Risk Factors for RFS, Relapse, and NRM in Patients Conditioned With BU/TBI: Multivariate Analysis*
Endpoint, RR (CI)
Risk Factor RFS Relapse NRM
Cytogenetic risk (favorable: good/intermediate) 2.6 (1.4, 4.9) 6.6 (2.3, 18.6) —†
P = .004 P = .0004
Disease duration (favorable: <12 months) 3.1 (1.6, 5.9) — 4.9 (2.3, 10.7)
P = .002 P = .0002
Patient CMV status (favorable: negative) — — 2.4 (1.1, 5.2)
P = .02
Patient sex (favorable: female) — — 2.6 (1.1, 6.0)
P = .02
*RR indicates relative risk; CI, conﬁdence interval.
†Not signiﬁcant.
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addition, male patient sex (P = .02) and positive CMV serol-
ogy of the patient (P = .02) were associated with higher
NRM. Patient age, etiology of MDS, donor (related versus
unrelated), and Bu Css levels did not have predictive value
for the endpoints studied.
Comparison to Historical Controls
Outcome data among BU/TBI conditioned patients
(present trial), BU/CY/TBI conditioned patients, and
CY/TBI conditioned patients as reported previously [11] are
summarized in Table 5. We refrained from carrying out
formal statistical analyses of results obtained with these
3 regimens for several reasons: patients underwent trans-
plantations over an interval of more than 17 years; over this
interval, many aspects of patient management have changed
considerably; some disease parameters required, for exam-
ple, for IPSS scoring, were not available for earlier patients.
An informal comparison of results suggests that 1 of the
objectives of the present study, achieving a low frequency of
relapse, was met. Use of BU/TBI and omission of CY did
not result in an increased incidence of relapse. Further, for
patients receiving transplants from HLA-matched related
donors, NRM was lower and RFS tended to be higher than
the outcomes observed with BU/CY/TBI. For unrelated
transplant recipients, on the other hand, NRM remained
high, and RFS was not improved in comparison to
BU/CY/TBI conditioned patients. In comparison to results
with a CY/TBI regimen, relapses tended to be less frequent,
the incidence of NRM somewhat higher, and the probability
of RFS comparable with the present BU/TBI regimen.
The incidence of acute GVHD in BU/CY/TBI and
CY/TBI conditioned patients was in the range of 65% to
71% compared to about 84% in the current trial. However,
these figures are difficult to compare, because more than
70% of patients in previous trials received transplants from
HLA-identical sibling donors compared to only 28% in the
current trial. The number of those transplants (n = 17) was
too small to allow for detailed statistical analysis.
DISCUSSION
Patients with advanced MDS (by FAB criteria) and with
high-risk scores (by IPSS) generally have short life
expectancies [2]. The major causes of death are complica-
tions related to peripheral blood cytopenias and progression
to AML. About half of the patients with advanced MDS
respond to chemotherapy as used for patients with de novo
AML [31,32]; however, remissions are usually of limited
duration, and few, if any, patients appear to be cured.
The most promising currently available therapy for
MDS is HSCT [3,5,9,10,12-15,33]. Most of the published
information comprises results with allogeneic transplanta-
tions [3,5,8-15,33], although recent data suggest that a pro-
portion of patients who achieve a complete remission with
induction chemotherapy can be consolidated successfully
with autologous HSCT [34]. However, posttransplantation
relapse, nonrelapse (treatment-related) mortality, and for
allogeneic transplants, donor availability have hampered
progress with this approach [7,11,13,14]. Trials at our center
revealed a high rate of relapse with a conditioning regimen
that combined CY and TBI and a reduced incidence of
relapse but high NRM with a combination of BU, CY, and
TBI [10,11]. Results of the current study show that a combi-
nation of BU plus TBI was effective in securing engraftment
from related as well as unrelated donors. No graft failure
was observed, and the tempo of hemopoietic recovery was
similar to that observed with a CY/TBI regimen [10].
Among related transplant recipients, NRM was reduced in
comparison to BU/CY/TBI conditioned patients, and the
Figure 2. Impact of pretransplantation clonal cytogenetic ﬁndings on
posttransplantation outcome in patients with advanced MDS condi-
tioned with BU and TBI. Shown are results among patients with poor
risk compared to those with good or intermediate risk karyotypes. X
indicates censored patients. A, Relapse (P = .0004). B, Relapse-free sur-
vival (P = .004).
Table 5. Comparison of Outcomes (%) at 3 Years Among BU/TBI,
BU/CY/TBI, and CY/TBI Conditioned Patients With RAEB, RAEB-T, 
or CMML
Conditioning Regimen
BU/TBI* BU/CY/TBI CY/TBI
Endpoint (Present Trial) [11] [11]
All patients, n 45 31 44
RFS, % 31 23 30
Relapse, % 18 19 39
NRM, % 51 57 32
Among HLA-identical siblings, n 16 22 33
RFS, % 31 15 27
Relapse, % 31 27 46
NRM, % 38 58 27
*Excluding secondary AML.
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relapse rate was not increased, particularly when patients
with sAML, who were enrolled in the present but not in the
previous studies, were excluded. As a result, RFS was
improved above that achieved with a BU/CY/TBI regimen.
Among unrelated recipients, the relapse rate was low [3],
but NRM was high after BU/TBI conditioning [11,15], and
as a result, RFS (25%) was not improved above that
achieved in previous trials. Overall, these results are compa-
rable to those reported by several American and European
groups using various conditioning regimens [3,8,12,33,34].
The data are also consistent with the notion that CY does
not have a major role as an antileukemic agent in these regi-
mens but adds to nonhemopoietic toxicity.
The incidence of GVHD in the present BU/TBI trial
was high and, particularly among related recipients, albeit in
a small number of patients, was above previously reported
ﬁgures. The reasons are not immediately apparent. Condi-
tioning with BU/TBI represents high-intensity therapy, and
a correlation of GVHD and conditioning intensity has been
recognized [35]. However, the previously used regimen had
employed 3 agents, BU, CY, and TBI, and at least among
patients who received MTX plus CSP for GVHD prophy-
laxis, GVHD incidence was not in excess of that expected
[6]. One presumably important difference between the pres-
ent (BU/TBI) study and the 2 patient cohorts studied previ-
ously (BU/CY/TBI and CY/TBI) was a longer interval from
diagnosis to transplantation (12 months versus 5 and
8.5 months, respectively). Prolonged disease duration is
generally also correlated with prolonged transfusion support
and increased colonization by infectious organisms and is
associated with organ (eg, liver) damage. These alterations
in turn may enhance the clinical manifestations of GVHD
and conceivably even lead to a misdiagnosis of GVHD. As
discussed elsewhere [36,37], patients with MDS often show
severe dysregulation of cytokines such as interleukin-1,
tumor necrosis factor α, and Fas ligand. These molecules
are also involved in the manifestations of GVHD [38]. It is
conceivable that signaling mediated via those molecules is
modulated by the type of conditioning regimen used and
ampliﬁed in patients with MDS. BU steady-state plasma lev-
els were not signiﬁcantly associated with GVHD or any of
the endpoints studied [39]. Finally, assessment of GVHD to
some extent is subjective, and several studies have shown
considerable interobserver variations that may contribute to
ﬂuctuations in the reported incidence of GVHD [40,41].
Relapses of MDS occurred to a large extent in patients
with poor cytogenetic risk and high IPSS scores. This out-
come is in agreement with a previously reported retrospective
analysis of results in 251 patients with MDS from our group
[4]. Similar data have been reported by Nevill et al. [3]. Other
investigators did not ﬁnd a signiﬁcant impact of IPSS score,
presumably because most patients included in those studies
qualified as high risk by IPSS criteria [34]. The observed
lower relapse rate among recipients of unrelated transplants
in the present trial was reminiscent of results in patients who
received transplants for other malignant hematologic disor-
ders and is thought to be related to a greater allogeneic effect
of unrelated donor cells [42-44]. Such a pattern suggests a
role for immunotherapy with allogeneic cells in patients with
MDS. In fact, 1 patient in the present BU/TBI trial who
relapsed after transplantation was given a donor lymphocyte
infusion and achieved a complete and lasting CR. Conceiv-
ably, therefore, immunologic effects of donor cells can be
exploited therapeutically in patients with MDS [44].
The impact of pretransplantation chemotherapy on
long-term outcome in patients with MDS is not well
defined. Whereas some authors found lower relapse rates
and superior RFS among patients who underwent transplan-
tations in chemotherapy-induced remission [3,9], others
observed no reduction in relapse rates and, in fact, compara-
ble or inferior outcome due to increased NRM [12,34]. In
the present trial, outcome in patients who received pretrans-
plantation therapy was poor—only 3 of 18 such patients are
surviving in continuous remission—but the small numbers
do not allow for ﬁrm conclusions.
The effect of CMV seropositivity on transplantation out-
come has been discussed extensively in the literature [12,45].
The availability of potent antiviral agents and the prospective
monitoring for CMV antigenemia, allowing for initiation of
preemptive therapy, have signiﬁcantly reduced the incidence
of CMV disease and CMV-related mortality [46,47]. In
agreement with those data, data from the present trial indi-
cate that CMV disease was not a major cause of death, and it
is not clear why CMV seropositivity of patients was a signiﬁ-
cant risk factor for NRM. Conceivably, tissue damage associ-
ated with reactivation of the virus was a contributing factor to
organ failure. Also, recent data suggest interactions between
CMV and invasive aspergillus infections (K. Marr, MD,
unpublished data, December 2001), a complication that
accounted for several deaths in the present study.
Inferior posttransplantation outcome due to higher NRM
in male compared to female patients has also been reported
by others [9]. Although the reasons are not clear, they may be
related to hormonal effects, social habits (eg, tobacco, alcohol
consumption), or environmental (eg, occupational) exposures.
To what extent the pathophysiologic mechanisms involved
in MDS may contribute to transplantation-associated NRM
remains speculative. It is of note, nevertheless, that many
patients with MDS express high levels of proinﬂammatory
cytokines and apoptosis-inducing signals, all of which are also
involved in the pathophysiology of GVHD and tissue destruc-
tion [37,38,48,49]. Additional studies are needed.
In conclusion, a BU/TBI regimen was effective in secur-
ing engraftment of hemopoietic stem cells from related and
unrelated donors. The incidence of posttransplantation
relapse tended to be lower than observed historically in
patients conditioned with CY/TBI and comparable to that in
patients prepared with the triple-agent regimen BU/CY/TBI.
The relapse incidence was particularly low in patients without
high-risk cytogenetics. Overall, however, improvements over
previously reported results were marginal, particularly in
unrelated transplant recipients, and we do not recommend
the use of the BU/TBI regimen described here in patients
with MDS. Future trials should investigate the efficacy of
reduced-intensity conditioning regimens.
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